BioSpace News Archive

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, announced that it intends to offer and sell shares of its common stock and warrants to purchase common stock in an underwritten public offering pursuant to an existing shelf registration statement.

HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that internationally renowned physician-scientist Jerald Radich, M.D., a pioneer in the fields of leukemia research and molecular genetics, has joined HTG’s Therapeutics Scientific Advisory Board.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) today announced that, as planned and announced earlier this year, CEO Dale R. Pfost, PhD will assume the additional role of Chairman, subject to the approval of Chemomab’s shareholders, as is required under Israeli law.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA),, today announced the initiation of clinical development of TSHA-118 for the treatment of CLN1 disease under a recently approved Clinical Trial Application (CTA).

Scitara Corporation, an innovator in laboratory digital transformation, has launched a ground-breaking advanced integration platform that creates a new industry category for the laboratory and scientific communities.

DENTSPLY SIRONA Inc., announced that its Board of Directors declared a quarterly cash dividend of $0.11 per share of common stock, an indicated annual rate of $0.44 per share.

Coherus BioSciences, Inc., announced that effective Dec. 13, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 367,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $17.06, the closing trading price on the grant date.

Ethos Laboratories, a College of American Pathologists-accredited and a certified leader in diagnostic testing services, announced today the launch of Tru-Immune™ — a finger prick, self-collection kit for its COVID-19 neutralizing antibody test. The simple test allows individuals to safely, quickly, and effectively obt

Kite, a Gilead Company, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that YESCARTA® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, will be available to patients with relapsed or refractory large B-cell lymphomas in Japan through the first treatment center now authorized by Daiichi Sankyo.

Transcenta Holding Limited, a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the appointment of Daniel Weng as the company’s CFO, reporting to Xueming Qian, CEO.